Neomorph
PrivateLast Round
Series B
Apr 13, 2026
Total Funding Raised
$209M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Neomorph operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in April 2026.
Neomorph is a biotechnology company that develops molecular glue degraders to target and destroy disease-causing proteins that have historically been considered undruggable.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neomorph Comparables
Compare Neomorph with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GluBio Therapeutics | 88% | |
| TRIANA Biomedicines | 87% | |
| Magnet Biomedicine | 87% |
For institutional investors. Book with your work email.
Neomorph Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 13, 2026 | ||||
| Series A | Dec 22, 2020 | ||||
| Seed | Mar 31, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neomorph Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B, Series A |
| Binney Street Capital | Series B |
| Alexandria Venture Investments | Series B |
| Longwood Fund | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Grew 15% QoQ, from 84 to 97 employees.
- Apr 14, 2026
Partnering with the Center for Protein Degradation at Dana-Farber Cancer Institute.
For institutional investors. Book with your work email.
Neomorph Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neomorph's valuation, stock price, and market status.
Is Neomorph a public or private company?
Neomorph is a private company.
What is the current stock price of Neomorph?
Neomorph is a private company, so its shares have no public market price. Caplight tracks Neomorph's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neomorph worth (valuation)?
Valuation information for Neomorph is not publicly available.
Can I buy Neomorph stock?
Neomorph shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neomorph's last funding round?
Neomorph's most recent funding round was Series B on April 13, 2026.
Who are the main investors in Neomorph?
Key investors in Neomorph include Deerfield Management.
Will Neomorph IPO soon?
No public IPO plans have been announced for Neomorph.
How can I track Neomorph secondary market activity?
Caplight tracks bids, offers, and trades in Neomorph's shares on secondary markets.